Health Canada
Health Canada Approves Rhythm Pharmaceuticals' Weight Management Drug for Patients With MC4R Variants
Imcivree, already approved in the US and UK, will be available for adult and pediatric patients at least 6 years of age with obesity due to certain genetic mutations.
Colorectal Cancer Canada, which led the survey, will share the data with decisionmakers, hoping to increase understanding of access barriers and change health policy.
Sermonix Expands Lasofoxifene Breast Cancer Study to Canadian Sites
Sermonix will launch the ELAINE-1 study at Exactis Innovation network sites across Canada to study the activity of its drug in ESR1-mutated breast cancer.